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Cervical cancer remains a major problem in women's health worldwide. In this research, a novel biodegradable d-α-
tocopheryl polyethylene glycol 1000 succinate-b-poly(ε-caprolactone-ran-glycolide) (TPGS-b-(PCL-ran-PGA))
nanoparticle (NP) was developed as a co-delivery system of docetaxel and endostatin for the synergistic treatment
of cervical cancer. Docetaxel-loaded TPGS-b-(PCL-ran-PGA) NPs were prepared and further modified by
polyethyleneimine for coating plasmid pShuttle2-endostatin. All NPs were characterized in size, surface charge,
morphology, and in vitro release of docetaxel and pDNA. The uptake of coumarin 6-loaded TPGS-b-(PCL-ran-PGA)/
PEI-pDsRED by HeLa cells was observed via fluorescent microscopy and confocal laser scanning microscopy.
Endostatin expression in HeLa cells transfected by TPGS-b-(PCL-ran-PGA)/PEI-pShuttle2-endostatin NPs was detected
using Western blot analysis, and the cell viability of different NP-treated HeLa cells was determined by MTT assay.
The HeLa cells from the tumor model, nude mice, were treated with various NPs including docetaxel-loaded-TPGS-
b-(PCL-ran-PGA)/PEI-endostatin NPs, and their survival time, tumor volume and body weight were monitored
during regimen process. The tumor tissue histopathology was analyzed using hematoxylin and eosin staining, and
microvessel density in tumor tissue was evaluated immunohistochemically. The results showed that the TPGS-b-
(PCL-ran-PGA)/PEI NPs can efficiently and simultaneously deliver both coumarin-6 and plasmids into HeLa cells, and
the expression of endostatin was verified via Western blot analysis. Compared with control groups, the TPGS-b-
(PCL-ran-PGA)/PEI-pShuttle2-endostatin NPs significantly decreased the cell viability of HeLa cells (p < 0.01),
inhibited the growth of tumors, and even eradicated the tumors. The underlying mechanism is attributed to
synergistic anti-tumor effects by the combined use of docetaxel, endostatin, and TPGS released from NPs. The
TPGS-b-(PCL-ran-PGA) NPs could function as multifunctional carrier for chemotherapeutic drugs and genetic
material delivery, and offer considerable potential as an ideal candidate for in vivo cancer therapy.
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Cervical cancer caused by high-risk human papilloma-
virus (HPV) persistent infection is the second most
common cancer in women worldwide [1,2]. Fortunately,
two HPV vaccines (Gardasil (Merck Sharp & Dohme
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in any medium, provided the original work is pUK)) have been approved for use in many countries that
would effectively reduce the incidence of cervical cancer
genesis. However, these two vaccines have not shown
any therapeutic effect against current cervical cancer,
HPV infections or associated lesions [3]. Thus, there are
urgent needs to develop new specific drugs or novel
therapeutic methods for cervical cancer treatment.
It has been well established that the progression of
solid tumors, including cervical cancer, is critically
dependent on neoangiogenesis for nutrition and oxy-
gen supply. Therefore, blockade of neoangiogenesis has
been regarded as a promising strategy for tumorpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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lytic fragment of collagen XVIII, has received the
greatest attention for its broad-spectrum and low-toxic
anti-angiogenesis ability [6,9,10]. These advantages ac-
celerate the investigation process of endostatin into the
clinical trial [11,12]. However, as a protein, endostatin
has many challenges in its clinical application, such as
short half-life and instability. Recently, gene therapy,
the use of DNA as a pharmaceutical agent, has been
extensively studied in a broad range of diseases includ-
ing tumors, which can achieve a relative long-term
stable expression of therapeutic proteins [13-16]. A
major limitation of gene therapy is the efficient deliv-
ery of therapeutic DNA to the target cells and tissues.
The main vectors for DNA delivery are viral vectors
and non-viral vectors having great advantages in safety,
convenient large-scale production, physiological stabil-
ity, and no immunogenicity.
Currently, a variety of particulate drug delivery sys-
tem based on synthetic and natural materials has been
investigated as DNA carriers, including liposomes
[17], dendrimers [18], polycationic polymers [19,20],
and polymeric nanoparticles (NPs) [21]. Among them,
PEI-based NPs are considered as one of the most ef-
fective carrier since it can complex with pDNA or
siRNA and exhibit a unique ‘proton sponge effect’ for
endosomal release of the nano-complexes into cytosol
[22]. On the other hand, many chemotherapeutic
drugs such as paclitaxel, doxorubicin and mitomycin
are also limited because of low water solubility, acute
toxicity to normal tissues due to lack of targeting,
and multi-drug resistance. Several researches showed
that the combination of endostatin and chemothera-
peutic drugs such as docetaxel can result in better in-
hibitory effects for tumor growth than single therapy
[23]. However, the clinical applications of these com-
bined drugs are needed to develop new efficient drug
delivery system.
A novel biodegradable copolymer d-α-tocopheryl
polyethylene glycol 1000 succinate-b-poly(ε-caprolac-
tone-ran-glycolide) (TPGS-b-(PCL-ran-PGA)) has been
successfully synthesized in our laboratory [24]. Our
previous research has confirmed that docetaxel-loaded
TPGS-b-(PCL-ran-PGA) NPs can be efficiently uptaken
by MCF-7 cells and effectively inhibit the growth of
tumor over a longer period of time than commercial
TaxotereW (Sanofi-Aventis US LLC, NJ, USA) at the
same dose. To overcome the limitations of single ther-
apy, we modified the TPGS-b-(PCL-ran-PGA) NPs
with a polyplexed PEI and evaluated its ability to sim-
ultaneously deliver DNA and a chemotherapeutic drug
in cells. Most importantly, we examined its therapeutic
effect on xenograft models bearing cervical cancer
cells.Methods
Polymers and reagents
TPGS-b-(PCL-ran-PGA) copolymer (Mw approximately
24,000) was synthesized in our laboratory (Tsinghua
University, China). Poly (vinyl alcohol) (PVA; (80%
hydrolyzed), dichloromethane, branched polyethyleni-
mine (MW approximately 25,000, BPEI25k) and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) kit were purchased from Sigma-Aldrich Corpor-
ation (MO, USA). 4',6-diamidino-2-phenylindole (DAPI)
was purchased from VECTOR (Burlingame, USA). Dul-
becco's Modified Eagles' Medium (DMEM), penicillin-
streptomycin, fetal bovine serum (FBS), and Dulbecco's
phosphate buffered saline (DPBS) were purchased from
Invitrogen-Gibco (Carlsbad, CA). Plasmid vectors pShut-
tle2, pIRES-EGFP, and pDsRED-E1 were acquired from
Invitrogen Corporation (Clontech, USA).Preparation of expression vectors
Human endostatin gene was amplified by PCR using the
following primers: hEndostatin-F: 50-GCTCTAGA(XbaІ)
gccaccatgggaattcatgcacagccaccgcgacttcc-30 and hEndos-
tatin-R: 50-GGGGTACC (KpnІ)ttacttggaggcagtcatg-30.
PCR products were digested with Xba I and KpnІ and
inserted into pShuttle2 vector (Clontech). The recom-
binant plasmid pShuttle2-endostatin was verified by
DNA sequencing. The expression of endostatin in HeLa
cells transfected with PEI or TPGS-b-(PCL-ran-PGA)-
based NPs was analyzed by Western blot analysis.Preparation of docetaxel-loaded TPGS-b-(PCL-ran-PGA)
NPs and determination of drug contents
Docetaxel-loaded and blank TPGS-b-(PCL-ran-PGA)
NPs were prepared using a modified water-in-oil-in-
water solvent evaporation as described previously [25].
Briefly, TPGS-b-(PCL-ran-PGA) copolymer (50 mg) and
a certain amount of docetaxel (0 to 25mg) were dis-
solved in 2 ml methylene chloride, followed by 30-s
sonication to emulsify the mixture (UW 70/HD 70; tip,
MS 72/D; Bandelin Electronic GmbH & Co., Berlin,
Germany). After the addition of 3 ml of 7% (w/v) aque-
ous solution of PVA, the emulsion was sonicated again
for 20 s. The resulting double emulsion was then poured
into 50 ml 1% (w/v) aqueous PVA solution containing
2% isopropanol and then maintained under mechanical
stirring for 1 h at 600 rpm. The residual methylene
chloride was then evaporated by vacuum. Next, the 2 ml
aliquots of the nanosphere suspension were washed
twice with 20 mM 4-(2-hydroxyethyl)-1-piperazineetha-
nesulfonic acid (HEPES)/NaOH (pH 7.0), and the NPs
were harvested by centrifugation at 7,000 rpm for 10
min. In addition, the fluorescent coumarin-6 loaded
TPGS-b-(PCL-ran-PGA) NPs were prepared in the same
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instead of docetaxel.
The docetaxel-loading content, defined as the mass
percentage of docetaxel entrapped in nanoparticles, was
quantified using UV–vis analysis (UV-2000 UV–vis spec-
trophotometer, Unico Inc., WI, USA). First, docetaxel-
loaded nanoparticle solutions were lyophilized to yield the
solid nanoparticle samples. Then, the dried nanoparticle
samples were weighed and redissolved in a mixture of
chloroform and DMSO (1:1, v/v). The absorbance of doce-
taxel at 482.5 nm was measured, and the drug content in
the solution was calculated based on a previously estab-
lished calibration curve.
Preparation of PEI-modified TPGS-b-(PCL-ran-PGA) NPs/
DNA complexes
The NPs were prepared as described previously [25].
Briefly, the particles were formulated with a ratio of the
polymer nitrogen to the DNA/phosphate (N/P) equal to
TPGS-b-(PCL-ran-PGA) NP solution (0.2 ml) and were
mixed with 2 mg of PEI in sterile HEPES-buffered saline.
The PEI-modified TPGS-b-(PCL-ran-PGA) NP solution
was then added to the plasmid DNA solution at different
N/P ratios and vortexed gently. The PEI-modified TPGS-
b-(PCL-ran-PGA) NP/DNA complexes were incubated in
sterile PBS for 20 min at room temperature.
Characterization of nanoparticles
The mean particle size and size distribution were mea-
sured using dynamic light scattering (DLS) (Zetasizer
Nano ZS90, Malvern Instruments Ltd., Malvern, UK). In
brief, the NPs were suspended in deionized water at a
concentration of 0.1 mg/ml. The mean hydrodynamic
diameter was determined via cumulative analysis. The
DLS determinations were predicated based on the elec-
trophoretic mobility of the NPs in an aqueous medium.
The electrophoretic mobility was evaluated using folded
capillary cells in an automatic mode. Zeta potential of
the NPs was detected using laser Doppler anemometry
(LDA; Zetasizer Nano ZS90, Malvern Instruments Ltd.).
Samples were prepared in PBS and diluted 1:3 with deio-
nized water to ensure that the measurements were per-
formed under conditions of low ionic strength where the
surface charge of the particles can be measured accurately.
The final concentration of the polymer was 0.01 mg/ml.
All data represent five measurements from one sample.
Gel retardation assay
The binding of pDNA with free TPGS-b-(PCL-ran-
PGA)/PEI NPs was determined by 0.8% agarose gel elec-
trophoresis. A series of different weight ratios (w/w) of
pDNA to NPs was loaded on the agarose gel (10 μl of
the sample containing different amounts of pDNA). ThepDNA bands were then visualized under a UV transillu-
minator at a wavelength of 365 nm.Evaluation of loading efficiency of pDNA to the NPs
The loading efficiency of pDNA to the NPs was evalu-
ated by measuring unbound pDNA in the NPs solution.
The supernatant in the loaded docetaxel or free TPGS-
b-(PCL-ran-PGA)/PEI NPs solution was recovered by
removing the NPs by centrifugation. Free pDNA concen-
tration in the supernatant was determined by measuring
absorbance at 260 nm using a UV-2550 spectrophotom-
eter (Shimadzu Corp., Kyoto, Japan). Loading efficiency
of pDNA in NPs was determined by subtracting the
amount of pDNA recovered in the washing solutions
from initial amount of pDNA added. Encapsulation effi-
ciency was defined as the percentage of pDNA encapsu-
lated in NPs with respect to the initially added amount
of pDNA.In vitro drug release
NPs with 15 mg docetaxel-loaded TPGS-b-(PCL-ran-
PGA) were dispersed in 5 ml release medium (phosphate
buffer solution of pH 7.4 containing 0.1% w/v Tween 80)
to form a suspension. Tween 80 was used to increase
the solubility of docetaxel in the buffer solution and
avoid the adherence of docetaxel to the tube wall. The
suspension was transferred into a dialysis membrane bag
(Spectra/Por 6, MWCO = 1,000, Spectrum Laboratories,
Inc., TX, USA). Then, the closed bag was put into a cen-
trifuge tube and immersed in 15-ml release medium.
The tube was put in an orbital water bath at 37°C under
a 120 rpm horizontal shaking. Ten milliliters of solution
was periodically removed for analysis and was replaced
with fresh release medium. The collected samples were
mixed in a mixture of chloroform and DMSO (1:1, v/v).
The analysis procedure was the same as described
above.
To investigate the in vitro release of pDNA, 5 mg of
TPGS-b-(PCL-ran-PGA)/PEI-25K (n = 6) and coumarin-
6-loaded TPGS-b-(PCL-ran-PGA)/PEI (n = 6) were
incubated in 1 ml of DPBS buffer (pH 7.4) in a micro-
centrifuge tube in shaking incubator at 37°C. After in-
cubating for 24 h, half of the samples (n = 3) were
transferred into a 25 mM sodium acetate buffer (pH 5.0)
to simulate acidication of the endolysosome of the cell.
Samples were taken periodically in microcentrifuge tubes
and were centrifuged at 14,000 rpm for 10 min to obtain
pellet NPs. The supernatants were removed and replaced
with fresh buffer, and NPs were resuspended by vigorous
pipetting. The supernatants were stored at −70°C until
analysis by UV measurement. Unmodified TPGS-b-
(PCL-ran-PGA) NPs were also analyzed as a background
control.
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HeLa and 293T cells (ATCC, VA, USA) were cultured in
DMEM, pH 7.4, supplemented with 25 mM NaHCO3,
10 μg/ml streptomycin sulfate, 100 μg/ml penicillin G,
and 10%(v/v) FBS. Cells were maintained at 37°C in a 5%
CO2, 95% air incubator.
Cell viability
The cytotoxicity of the NPs was determined using MTT
assay. The culture medium was removed and replaced
with 20 μl/well MTT (5 mg/ml) solution in each well,
followed by 4-h incubation at 37°C in a fully humidified
atmosphere with 5% CO2. MTT was taken up by active
cells and transformed into insoluble purple formazan
granules in the mitochondria. Subsequently, the medium
was discarded, the precipitated formazan was dissolved
in DMSO (150 μl/well), and optical density of the solu-
tion was evaluated using a microplate spectrophotom-
eter at a wavelength of 570 nm. The analytic assays were
performed every day, and at least 4 wells were randomly
taken into examination each time. The determination of
cell viability depends on these physical and biochemical
properties of cells.
Cellular uptake of PEI-modified TPGS-b-(PCL-ran-PGA) NPs
The cells were plated in a 6-well (3 × 105 per well) plate,
cultured at 37°C in 5% CO2, rinsed twice, and pre-
incubated for 1 h with 2 ml of serum-free medium at
37°C. Coumarin-6-loaded TPGS-b-(PCL-ran-PGA)/PEI
NPs with or without pDsRED or pIRES-EGFP were
added in a particle concentration of 0.01 to 0.2 mg/ml
and incubated for 1 to 4 h at 37°C. The cells were then
washed three times with 1 ml of PBS (pH 7.4) to remove
free PEI/plasmids-modified TPGS-b-(PCL-ran-PGA)
NPs, resuspended in PBS, and then analyzed by fluores-
cent microscopy.
For confocal laser microscopy analysis, cells were pre-
incubated for 1 h at 37°C in serum-free medium and
then for 30 min to 4 h in the presence of PEI/plasmids
pIRES-EGFP or/and pDsRED gene-modified TPGS-b-
(PCL-ran-PGA) NPs with a final particle concentration
of 0.05 mg/ml. The samples were mounted in fluores-
cent mounting medium (Dako, Glostrup, Denmark), and
fluorescence was monitored. Images were acquired using
a confocal laser microscope (Eclipse TE 2000, Nikon
Corporation, Tokyo, Japan).
Western blot
The cells were seeded into 6-well plates overnight,
allowed to attach the bottom. Cells were cultured at 37°C
in 5% CO2, rinsed twice, and pre-incubated for 1 h with
2 ml of serum-free medium at 37°C. Endostatin gene-
modified TPGS-b-(PCL-ran-PGA) NPs were added in
a particle concentration of 0.01 to 0.2 mg/ml andincubated for 1 to 4 h at 37°C. The cells were then
washed three times with 1 ml PBS (pH 7.4) to remove
any free PEI/plasmid-modified TPGS-b-(PCL-ran-PGA)
NPs. After being cultured in fresh complete medium for
48 h, the cells were lysed with lysis buffer (Beyotime In-
stitute of Biotechnology, Haimen, Jiangshu, China) con-
taining PMSF (Sigma Chemical Co., St. Louis, MI, USA)
for 30 min at 4°C. The lysate was then centrifuged for 20
min at 13,000 rpm and 4°C. The proteins were then sepa-
rated through SDS-PAGE and transferred onto the PVDF
membrane (Immobion-P Transfer Membrane, Millipore
Corp., Billerica, MA, USA). Membranes were blocked in
a tris-buffered saline with 0.1% Tween 20 solution con-
taining 5% non-fat dry milk and incubated overnight with
anti-human endostatin antibody as primary antibody at
4°C. Anti-β-actin antibody was used as loading control.Mice maintenance and subcutaneous tumor model
Female BALB/c-nu/nu mice were supplied by the Med-
ical Experimental Animal Center of Guangdong Prov-
ince (Guangdong, China). A subcutaneous tumor model
of nude mice was constructed. Six-week-old female nude
mice (18 ± 2 g) were subcutaneously inoculated with 1.5
to 2 × 106 HeLa cells. When the tumor size reached
about 100 mm3, the mice were randomly divided into
six groups with six mice each: PBS, TPGS-b-(PCL-ran-
PGA) (group ANP), TPGS-b-(PCL-ran-PGA)/PEI(group
BNP), TPGS-b-(PCL-ran-PGA)/PEI-pEndostatin (group
CNP), docetaxel-loaded TPGS-b-(PCL-ran-PGA) (group
DNP), and docetaxel-loaded TPGS-b-(PCL-ran-PGA)/
PEI-pEndostatin (group FNP), of which each dose of
NPs contained 0.2 mg PCL-PGA-TPGS, 10 μg PEI, and
50 μg pDNA for treatment. The groups were treated
once every 3 days with intratumoral injections of PBS or
NPs. Tumor size was measured with a caliper, and the
weight of each mouse was measured with a scale. Tumor
volume was calculated as the equation ‘volume = length
× width2 / 2’. The mean tumor volume and mouse
weight were used to construct the curves of tumor
growth versus mouse growth to evaluate therapeutic effi-
ciency and toxicity.
At the end of the treatment, the mice in each
group were killed and dissected. The heart, liver,
lungs, spleen, kidneys, and other organs were
checked for signs of toxicity. Tumor specimens were
then prepared as paraffin-embedded sections for
histopathological analysis. The study was carried out
in strict accordance with the recommendations in
the Guide for the Care and Use of Laboratory Ani-
mals of Institutional Animal Care and Use Commit-
tee of Graduate School at Shenzhen, Tsinghua
University. The protocol was approved by the Ani-
mal Welfare and Ethics Committee of Graduate
Figure 1 Expression of endostatin in HeLa cells using Western
blot analysis. Lane 1: HeLa cells were transfected by pShuttle2-
endostatin using PEI, lane 2: transfected by pShuttle2-endostatin
using TPGS-b-(PCL-ran-PGA)/PEI, lane 3: transfected by pShuttle2
using TPGS-b-(PCL-ran-PGA)/PEI.
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2011-YZ-BG).
Measurement of microvessel density in tumor tissues
Microvessel density (MVD) in tumor tissue was evalu-
ated immunohistochemically using a monoclonal anti-Figure 2 The size of different NPs (mean ± SD) (A). ANPs: TPGS-b-(PCL-
docetaxel-loaded TPGS-b-(PCL-ran-PGA)/PEI. The results showed that the si
modified by PEI. The zeta potential of the different NPs (B). The zeta poten
by PEI was positive and reduced after complexed with pDNA. The results s
retardation assay of pDNA complexed with TPGS-b-(PCL-ran-PGA)/PEI (C). E
modified TPGS-b-(PCL-ran-PGA) NPs was examined by FESEM (D)mouse CD31 antibody (rat anti-mouse CD31 monoclo-
nal antibody, clone MEC 13.3; BD Biosciences, NJ,
USA). Tumor samples were collected after the therapy
regimen was finished. Immunohistochemical staining
was performed as described previously [26]. MVD (%)
was calculated from the ratio of the CD31-positive stain-
ing area to the total observation area in the viable re-
gion. Three to six fields per section were randomly
analyzed, excluding necrotic areas. Positive staining
areas were calculated using imaging analysis software
(Win Roof; Mitani Corporation, Fukui, Japan).
Statistics and data analysis
All cell experiments were repeated at least three times
unless otherwise indicated. Images of Western blot
results from representative experiments were presented.
The figures were created using Adobe Photoshop CS
graphics program. All data were analyzed by paired t test
using SPSS 11.0 software. Differences were considered
statistically significant at P < 0.05.ran-PGA) NPs; DNPs: docetaxel-loaded TPGS-b-(PCL-ran-PGA) NPs; ENPs:
ze of NPs increased because of loading docetaxel and/or being
tial of blank NPs was negative; the zeta potential of the NPs modified
howed that TPGS-b-(PCL-ran-PGA) blank NPs could be modified. Gel
ach lane contained the same pDNA. Surface morphology of the PEI-
Figure 3 The in vitro release profile of pDNA from various NPs
at pH 7.4 and pH 5.0.
Figure 4 The in vitro release curve of docetaxel from different
NPs.
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The expression of pShuttle2-endostatin
Protein expression of endostatin was analyzed by West-
ern blot using cell lysate after transfection of HeLa cells
using PEI (Figure 1). These results showed that
pShuttle2-endostatin was successfully constructed and
expressed in HeLa cells.
Characterization of nanoparticles
Recently, a novel biodegradable copolymer, TPGS-b-
(PCL-ran-PGA), has been successfully synthesized in
our laboratory [24]. Our previous study showed that the
NPs made of this novel copolymer can improve drug per-
meability, solubility, degradation, and avoid the disadvan-
tages of single component [24]. More importantly, TPGS,
the degradation products of TPGS-b-(PCL-ran-PGA),
showed synergistic anticancer activity in the presence of
anticancer agents [24]. In this research, to co-delivery
chemotherapeutic drugs and genetic materials into cells,
TPGS-b-(PCL-ran-PGA) NPs were modified with cat-
ionic polymer PEI (25 K). DLS assay showed that the
hydrodynamic diameter of the polyplexed blank TPGS-b-
(PCL-ran-PGA) NPs (ANPs) was approximately 215 nm,
while the diameters of the docetaxel-loaded TPGS-b-
(PCL-ran-PGA) and docetaxel-loaded TPGS-b-(PCL-
ran-PGA) PEI-coated without pDNA NPs were approxi-
mately 242 and approximately 270 nm, respectively
(Figure 2A). The FESEM images showed that the morph-
ologies of TPGS-b-(PCL-ran-PGA)/PEI NPs were
sphere-like in shape, and the size was about 250 nm
(Figure 2D), consistent with the DLS data. The result
suggested that PEI modification may increase the size of
the NPs from TPGS-b-(PCL-ran-PGA) copolymer. In
addition, the surface charge of the unmodified TPGS-b-
(PCL-ran-PGA) NPs was approximately −18.25 mV
detected by LDA assay, while the surface charge of the PEI-
modified NPs was significantly increased in zeta potential,
suggesting that the surface charge of the TPGS-b-(PCL-ran-
PGA) NPs was altered from negative to positive due to the
PEI coating. However, a reduction in surface charge of the
PEI-modified NPs was observed after adding pDNA,
suggesting PEI condenses negatively charged DNA into
positively charged particles (Figure 2B). Agarose gel electro-
phoresis assay showed that the amount of NP-binding DNA
increased as the amount of TPGS-b-(PCL-ran-PGA)/PEI
NPs increased (Figure 2C). In a recent report, the DNA
encapsulated in the polymeric (PLGA) NPs is in a con-
densed form, which could protect itself from denaturation
and allow it to be efficiently taken up by MSCs [25]. An-
other study also showed that PLGA/PEI NPs can protect
DNA against degradation and reduce the cytotoxicity caused
by PEI [25]. Together, results showed that the TPGS-b-
(PCL-ran-PGA) NPs modified by PEI could encapsulate
docetaxel and DNA with a high loading efficiency.In vitro release
Previous study showed that the kinetic of NP degrad-
ation and DNA release appears to have a significant
regulatory effect on the gene expression [26]. In this
study, we compared the in vitro release of pDNA from
docetaxel-loaded or doceraxel-free TPGS-b-(PCL-ran-
PGA)/PEI-pDNA (DNPs or ENPs) formulations at pH
7.4 and pH 5.0. To simulate acidification in the endo-
lysosome of cells following intracellular uptake, NPs
were first incubated in a solution at pH 7.4 for 24 h,
then one-half of the NPs continued to be incubated at
Figure 5 The fluorescence microscopic images of 293T cells. This is after the incubation with plasmids pIRES-EGFP-loaded and pdSRED-
loaded TPGS-b-(PCL-ran-PGA)/PEI NPs; (A) from transmitted light channel, (B) from FITC channel, (C) from PI channel.
Figure 6 Confocal laser scanning microscopy of HeLa cells. This is after incubation with loaded-coumarin-6-TPGS-b-(PCL-ran-PGA)/PEI-
pDSRED NPs at 37°C. The cells were stained by DAPI (blue), and the plasmids pDsRED-loaded-TPGS-b-(PCL-ran-PGA)/PEI NPs are red. The cellular
uptake was visualized by overlaying images obtained. (A) Coumarin-6, (B) RED, (C) DAPI, and (D) co-merge.
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Figure 7 Viability of HeLa cells after 24- and 48-h incubations
(n = 5). Single asterisk denotes p < 0.05 (compared with PBS), while
double asterisk indicates p < 0.01 (compared with PBS).
Figure 8 The tumor volume curve after animal models were
treated by different NPs.
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pH 5.0. pDNA release was monitored by measuring UV
absorption at 260 nm at predetermined time points. In
the pH 7.4 group, 40.5% and 43.1% of the total pDNA
were released rapidly from docetaxel-loaded NPs/PEI
and empty NPs/PEI, respectively, at 48 h, followed by a
slow release until day 7 (Figure 3). These two formula-
tions had no significant difference either at initial burst
phase or slow release phase at pH 5.0, suggesting that
the loaded docetaxel had no significant influence on
pDNA release. Zolnik's group reported that cleavage of
the ester linkage of the PLGA polymer backbone at low
pH can accelerate the polymer erosion [27]. However, in
this study, the release kinetics of pDNA at pH 7.4 was
similar to that at pH 5.0, but the release of pDNA from
NPs from day 7 at pH 5.0 was more rapid than that at
pH 7.4. The reason was the degradation of surface ero-
sion [27]. Being a hydrophilic molecule located at the
surface of the TPGS-b-(PCL-ran-PGA) matrix, PEI may
facilitate the degradation of the NPs by increasing hydra-
tion and, thereby, accelerating hydrolysis [28].
In order to investigate the docetaxel release profiles,
the three formulations of NPs, docetaxel-loaded TPGS-
b-(PCL-ran-PGA), docetaxel-loaded TPGS-b-(PCL-ran-
PGA)/PEI, and docetaxel-loaded TPGS-b-(PCL-ran-PGA)/
PEI-pDNA, were incubated in 37°C aqueous solutions at
pH 7.4 and pH 5.0, respectively. As shown in Figure 4, a
typical release profile was observed for all six tested
nano-complex solutions, including an initial rapid re-
lease followed by a sustained slow release over a pro-
longed time up to several weeks. Furthermore, the
docetaxel release at pH 5.0 was faster than the other
nano-assemblies. Similar pH-dependent trend was also
observed in other docetaxel-loaded polymeric micellar
systems [29], and such behavior was assumed to improve
intracellular drug release once the nano-complexes enter
the tumor cells via endocytosis and trapped within the
acidic endosomal/lysosomal compartments. In addition,
both pDNA complexion and PEI coating were found to
prolong docetaxel release, which is consistent with the
results for a paclitaxel and Herceptin (Genentech, Inc.,
CA, USA) co-delivery system using cationic micellar NPs
[30]. These results implied that the release profile of PEI-
modified docetaxel-loaded TPGS-b-(PCL-ran-PGA) NPs
was prolonged, and its toxicity might be decreased.
Cellular uptake
To evaluate cellular uptake of nanoparticles, 293T or
HeLa cells were incubated with PEI-modified TPGS-b-
(PCL-ran-PGA) NPs and coumarin-6-loaded TPGS-b-
(PCL-ran-PGA) NPs for 48 h. The fluorescence emitted
by coumarin-6 and RED protein was observed after NP in-
cubation, which suggested that the NPs efficiently entered
the cells. The 293T cells took up the particles in a dose-dependent manner, and EGFP and RED expression
achieved peak levels with 1.5 mg/ml of PEI complexed with
100 mg of NPs (Figure 5). These findings demonstrated
that PEI-modified NPs may be good candidates for the
delivering of genes into tumor cells, and PEI-modified
TPGS-b-(PCL-ran-PGA) nanospheres may increase the
gene binding ability which causes the endosomal escape
easily and lowers the PEI cytotoxicity [25]. We also found
that more PEI-modified coumarin-6-loaded NPs were
uptaken by HeLa cells than unmodified NPs, which is in
consistency with other reports [31]. It was probably be-
cause the PEI-modified NPs had positive charge on surface,
Figure 9 The histopathological analysis of the tumor tissues from different treatment groups. (A) PBS, (B) ANPs (TPGS-b-(PCL-ran-PGA)),
(C) CNPs (TPGS-b-(PCL-ran-PGA/PEI/pEndo), (D) DNPs, (E) ENPs, and (F) FNPs
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tive charge on the surface. In addition, our data also
showed that coumarin-6 and RED protein can co-express
in HeLa cells transfected by coumarin-6-loaded TPGS-b-
(PCL-ran-PGA)/PEI-pDSRED (Figure 6), suggesting that
PEI-modified TPGS-b-(PCL-ran-PGA) can co-deliver che-
motherapeutic drugs and genetic materials into cells.Figure 10 MVD of tumor tissue in different treatment groups. Single a
denotes p < 0.01 (compared with PBS)Cell viability
Cytotoxicity of all NPs was determined in various con-
centrations using MTT assay. The cell viability was not
affected by TPGS-b-(PCL-ran-PGA) NPs in all concen-
trations relative to the control (treated with PBS) after
72 h in medium. However, increasing dosage of PEI-
modified TPGS-b-(PCL-ran-PGA) NPs was associatedsterisk indicates p < 0.05 (compared with PBS), while double asterisk
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PEI (Figure 7). As expected, for TPGS-b-(PCL-ran-
PGA), TPGS-b-(PCL-ran-PGA)/PEI NPs, and coumarin-
6-loaded NPs, the cell survival rates were greater than
84%, whereas cell survival rate of the cells treated with
equal dose of PEI was less than 70% (data not shown),
suggesting that TPGS-b-(PCL-ran-PGA) could reduce
the cytotoxicity of PEI (Figure 7). On the other hand,
docetaxel-loaded TPGS-b-(PCL-ran-PGA)/PEI-pEndos-
tatin NPs appeared to have more cytotoxicity than that
of the other control NPs including docetaxel-loaded
NPs; this may be because endostatin could induce cell
apoptosis [32]. Among all NPs, docetaxel-load NPs/PEI-
endostatin had the highest cytotoxicity.
The cell viability of HeLa cells transfected with
docetaxel-loaded NPs was decreased after 6 h, which
was dose- and time-dependent. These results indicated
that PEI-modified TPGS-b-(PCL-ran-PGA) NPs can
simultaneously delivery docetaxel and genetic materials
into cancer cells and kill them.
In vivo studies
To investigate the therapeutic effect of TPGS-b-(PCL-
ran-PGA)-based NPs on tumors, the anti-tumor efficacy
and angiogenesis inhibition of various NPs including
docetaxel-loaded NPs-PEI/pEndostatin were further eval-
uated in vivo. Subcutaneous tumor models were con-
structed in nude mice by being inoculated with 1 to 2 ×
106 HeLa cells. The results showed that CNPs, ENPs, and
FNPs containing docetaxel significantly inhibited tumor
growth compared with PBS, ANPs, and DNPs (p < 0.01)
(Figure 8). The tumor volume of the mice treated with
FNPs appeared to keep growing in the initial 5 days after
treatment, and then the tumor sites presented
inflammatory-like response and ulcer. After 3 weeks, the
tumor growth was significantly inhibited, and 80% tumor
was eradicated. Similar trend was also found in the groups
treated with CNPs and ENPs, the inhibitory effect was
better than other groups except of FNP treatment group.
Treatment of mice with docetaxel-loaded NPs and PEI-
modified docetaxel-loaded NPs inhibited 84% and 87%
in tumor growth inhibition efficiency, respectively, des-
pite no significant difference (p > 0.05).
Compared with the PBS group, the tumor growth inhib-
ition of the groups treated with empty NPs and NPs/PEI-
pEndostatin was 10% and 38%, respectively, which again
proved that endostatin could inhibit tumor growth. The
inhibitory effect of empty NPs may be caused by the TPGS
degradation from the NP matrix (Figure 8). The histo-
pathological analysis of the tumor tissues also revealed
that NPs containing docetaxel or/and endostatin induced
cell necrosis and apoptosis, leading to suppression of
tumor progression (Figure 9). MVD in FNP, DNP, and
CNP groups was relatively lower (p < 0.01) (Figure 10)compared with PBS group. MVD in DNP group was also
lower in contrast with PBS group (p < 0.05) (Figure 10).
This is due to the cell necrosis and apoptosis caused by
docetaxel and endostatin. These results are consistent
with histopathological analysis of the tumor tissues. No
significant difference in mouse weight was observed
among each NP treatment group (data not shown). At the
end of the experiment, dissection results revealed that
there were no obvious signs of toxicity in the heart, liver,
lungs, spleen, kidneys, and other organs in each group.
These results implied that TPGS-b-(PCL-ran-PGA)-based
NPs could serve as multifunctional carrier of docetaxel
and endostatin. In addition, during the regimen process,
the release of TPGS may help the anticancer effect of doc-
etaxel and endostatin because TPGS possesses the func-
tions to improve drug permeability, enhance absorption of
drugs, and reduce P-glycoprotein-mediated multi-drug
resistance in cancer cells by inhibition of P-glycoprotein
activity [33,34].
Conclusions
In this research, PEI-modified docetaxel-loaded TPGS-b-
(PCL-ran-PGA) NPs polyplexed with endostatin gene
showed an optimizing potential in delivering genes and
chemotherapeutic drugs. The co-delivery of endostatin
and docetaxel by PEI-modified TPGS-b-(PCL-ran-PGA)
NPs significantly inhibited the tumor growth of nude
mouse models (even regress 80% established tumor). In
conclusion, our study suggested that PEI-modified TPGS-
b-(PCL-ran-PGA) NPs could function as an optimizing
carrier for chemotherapeutic drugs and genetic materials.
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